These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Treatment of BRAF inhibitor-induced hyperkeratosis. Battley JE; Lenihan E; Redmond HP; Murphy M; Power DG Acta Oncol; 2013 May; 52(4):874-7. PubMed ID: 22998476 [No Abstract] [Full Text] [Related]
10. [New treatment options for metastatic melanoma]. Tietze JK; Berking C Dtsch Med Wochenschr; 2014 Jul; 139(28-29):1462-7. PubMed ID: 24983194 [No Abstract] [Full Text] [Related]
11. Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management. Zimmer L; Livingstone E; Hillen U; Dömkes S; Becker A; Schadendorf D Arch Dermatol; 2012 Mar; 148(3):357-61. PubMed ID: 22250191 [TBL] [Abstract][Full Text] [Related]
12. Evidence for upregulation of Bim and the splicing factor SRp55 in melanoma cells from patients treated with selective BRAF inhibitors. Lai F; Jiang CC; Farrelly ML; Zhang XD; Hersey P Melanoma Res; 2012 Jun; 22(3):244-51. PubMed ID: 22516966 [TBL] [Abstract][Full Text] [Related]
13. Complete Cytologic Remission of V600E BRAF-Mutant Melanoma-Associated Leptomeningeal Carcinomatosis Upon Treatment With Dabrafenib. Wilgenhof S; Neyns B J Clin Oncol; 2015 Oct; 33(28):e109-11. PubMed ID: 24733801 [No Abstract] [Full Text] [Related]
14. Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients. Vanneste L; Wolter P; Van den Oord JJ; Stas M; Garmyn M J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):61-8. PubMed ID: 24661317 [TBL] [Abstract][Full Text] [Related]
16. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma. Menzies AM; Long GV Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796 [TBL] [Abstract][Full Text] [Related]
17. BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency. Hong DS; Vence L; Falchook G; Radvanyi LG; Liu C; Goodman V; Legos JJ; Blackman S; Scarmadio A; Kurzrock R; Lizee G; Hwu P Clin Cancer Res; 2012 Apr; 18(8):2326-35. PubMed ID: 22355009 [TBL] [Abstract][Full Text] [Related]
18. Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma. Dika E; Patrizi A; Ribero S; Fanti PA; Starace M; Melotti B; Sperandi F; Piraccini BM Eur J Dermatol; 2016 Jun; 26(3):232-9. PubMed ID: 27019511 [TBL] [Abstract][Full Text] [Related]
19. Potassium iodide in successful treatment of erythema nodosum-like lesions induced by combination therapy with dabrafenib and trametinib. Sawada H; Kanehisa F; Katoh N; Asai J J Dermatol; 2020 Jan; 47(1):e7-e8. PubMed ID: 31587335 [No Abstract] [Full Text] [Related]
20. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. Long GV; Menzies AM; Nagrial AM; Haydu LE; Hamilton AL; Mann GJ; Hughes TM; Thompson JF; Scolyer RA; Kefford RF J Clin Oncol; 2011 Apr; 29(10):1239-46. PubMed ID: 21343559 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]